How many insider trades does FilingIQ track for OCGN?

FilingIQ tracks 174 Form 4 insider transactions for OCGN (Ocugen, Inc.), covering filings from Sep 30, 2019 onwards. 6 of those were filed in the last 90 days.

Are OCGN insiders net buyers or net sellers?

Across the full Form 4 history for OCGN, 30 transactions (17%) were open-market purchases and 64 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does OCGN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is OCGN in?

Ocugen, Inc. (OCGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $586.94M.

OCGN insider trading

NasdaqCM Healthcare

Ocugen, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

174

Last 90 days

Buys / sells

17% / 37%

Market cap

$586.94M

About Ocugen, Inc.

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Company website: www.ocugen.com

OCGN insider activity at a glance

FilingIQ has scored 174 insider transactions for OCGN since Sep 30, 2019. The most recent filing in our index is dated Apr 1, 2026.

Across the full history, 30 open-market purchases and 64 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on OCGN insider trades is 54.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live OCGN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for OCGN?: FilingIQ tracks 174 Form 4 insider transactions for OCGN (Ocugen, Inc.), covering filings from Sep 30, 2019 onwards. 6 of those were filed in the last 90 days.
Are OCGN insiders net buyers or net sellers?: Across the full Form 4 history for OCGN, 30 transactions (17%) were open-market purchases and 64 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does OCGN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is OCGN in?: Ocugen, Inc. (OCGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $586.94M.

Methodology & sources

Every OCGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.